Strong healthcare systems are targeting sophisticated drug delivery solutions, which are increasing the demand for liposomes
In 2024, the net value of the worldwide Liposome Market was calculated to be US$ 8,670.7 million, up from US$ 6,453.2 million in 2019. The entire market also saw a steep increase in sales during the pandemic years as a result of increased usage of liposomal vaccine delivery product lines. The market for liposomes is anticipated to grow at a 7% CAGR during 2024-2034. The net value of the world's liposome market is likely to be US$ 17,123.1 million in 2034.
Strong healthcare systems are targeting sophisticated drug delivery solutions, which are increasing the demand for liposomes
In 2024, the net value of the worldwide Liposome Market was calculated to be US$ 8,670.7 million, up from US$ 6,453.2 million in 2019. The entire market also saw a steep increase in sales during the pandemic years as a result of increased usage of liposomal vaccine delivery product lines. The market for liposomes is anticipated to grow at a 7% CAGR during 2024-2034. The net value of the world's liposome market is likely to be US$ 17,123.1 million in 2034.
Recent advances in drug delivery science have enhanced the significance and need for liposomal formulations in the pharma production industries. The increasing interest of today's healthcare systems in nanomedicine is likely to further increase the use of liposomes, especially those of liposomal nanoparticles.
Key Takeaways from the Liposome Market Study Report:
The overall demand for liposome drug carriers in North America is projected to fetch a revenue of approximately US$ 3,318 million in 2024.
The United States market is projected to be valued at approximately US$ 2,922 million in 2024.
The market for liposomal drug carriers in East Asia is projected to be worth 1,285 million in 2024.
China, boasting a vast pharmaceutical industry base, is still the market leader in East Asia and is projected to control over 50% of the market share in the region.
"Pharmaceutical company-liposome manufacturing industry research and development collaborations are still the strategy of choice to expand the business. Since drug delivery techniques are continuously changing, the market players have to invest increasingly in liposome delivery technology," states a Fact.MR analyst.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9589
Leading Players Driving Innovation in the Liposome Market:
Major companies in the liposome market are Novartis AG (Liposoma BV), Precision NanoSystems Inc., Janssen Pharmaceutical Companies (Johnson & Johnson), Encapsula Nano Sciences, Synpac-Kingdom Pharmaceutical Co., Ltd, Celsion GmbH, Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Sun Pharma Industries Ltd, Shanghai New Asia Pharmaceutical Co., Ltd., ENERGY DELIVERY SOLUTIONS, Creative Biolabs, Nanovex Biotechnologies SL, Insys Therapeutics Inc., Fujifilm Holdings Corporation, Virpax Pharmaceuticals, Azaya Therapeutics, Avanti Polar Lipids, Inc., Breath Therapeutics (Zambon company), Getwell, Taiwan Liposome Company Ltd, Fresenius Health Care Group, Xellia Pharmaceuticals (Novo Holdings A/S), Jazz Pharmaceuticals plc, Ipsen Biopharmaceuticals, Inc., Baxter, GMPriority Pharma, and S. G. Biopharm Pvt. Ltd.
Liposome Market Competitive Landscape:
A few leading players in the pharmaceutical industry supply over half of the world's demand for liposome formulation. The market is, therefore, concentrated in nature overall. Greater encouragement from federal bodies towards building the pharmaceutical industries in developing economies is expected to spread the market gradually in days to come.
Recent Activities by the Participants of Liposomes Industry:
Taiwan Liposome Company, Ltd. (TLC) and Endo International plc subsidiary Endo Ventures Limited (EVL) entered into an agreement for commercializing TLC599, which is still in the experimental phase. The partnership was announced during June 2022. The revolutionary TLC599 chemical is currently in stage 3 of the development cycle and can be injected to relieve the pain of arthritic knees. In a bid to increase therapy options, this pioneering medicine has been created by TLC that is Taiwan's clinical-stage specialty pharmaceutical.
In January 2022, Acuitas Therapeutics and Pfizer agreed on a development and option pact for intellectual properties collaboration. Upon this strategic partnership, Pfizer got a non-exclusive license option over Acuitas' lipid nanoparticle (LNP) technology to utilize on ten targets or less. It has possible vaccine and pharmaceutical study applications that could be utilized by Pfizer for innovative developments in the industry.
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9589
Emerging Drug Delivery: The Principal Growth Driver for Liposome Market
Liposome market is primarily growing as a result of increasing interest in advanced drug delivery systems among the pharmaceutical and biotechnology industries. Liposomes, being nanoscale vesicles that encapsulate hydrophilic and hydrophobic drugs, enhance the bioavailability of drugs, reduce toxicity, and enable targeted drug delivery. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and infectious diseases has fueled the application of liposomal drug formulations. In addition, ongoing research and development efforts to improve liposome stability, effectiveness, and large-scale production also fuel market growth. Market growth has also been aided by regulatory approvals for liposomal drug products, such as liposomal doxorubicin and amphotericin B.
Increased applications of liposomes in cosmeceuticals, nutraceuticals, and food products is another key driver. In the cosmetics and dermatology industry, liposomes enhance active ingredient delivery, increasing efficacy and penetration. Similarly, in the nutraceutical industry, liposomes are used to boost vitamin and supplement bioavailability, answering growing consumer demand for functional and fortified foods. Growing demand for nanotechnology-based drug delivery systems, along with innovation in manufacturing processes such as microfluidics and extrusion, is also enhancing market growth further. Also, growing biopharmaceutical research, collaboration between industry players on a strategic level, and enhanced government spending on nanomedicine are set to propel the increasing trend of the liposome market.
Checkout More Related Studies Published by Fact.MR Research:
The global ultrasound probe disinfection market , valued at US$ 551 million in 2023, is set to grow at a CAGR of 8.5%, reaching US$ 1.24 billion by 2033.
The medical sensors market , worth US$ 2.32 billion in 2023, is projected to reach US$ 6.59 billion by 2033, expanding at a CAGR of 10.2%.
The geriatric care services market , valued at US$ 468.5 million in 2023, is expected to grow at a 6.1% CAGR, reaching US$ 850 million by 2033.
The bioceramics market , valued at over US$ 14 billion in 2020, is forecasted to expand 1.5X to US$ 23 billion by 2031.
The medical laser systems market , worth US$ 4 billion in 2020, is projected to reach US$ 7.5 billion by 2031 at a CAGR of 8.5%, with surgical lasers alone reaching US$ 1 billion.
The medical membranes market , valued at US$ 2 billion in 2020, is expected to grow to US$ 3 billion by 2031 at a CAGR of 7%, with ultrafiltration membranes reaching US$ 1 billion.
The closed blood sampling systems market is set to grow at a CAGR of 5.9%, increasing from US$ 76.32 million in 2022 to US$ 135.83 million by 2032.
The surgical procedures volume market , valued at US$ 1.7 billion in 2020, is projected to reach US$ 2.6 billion by 2028, expanding at a 6% CAGR.
